WO2018221551A1 - Agent thérapeutique contenant un dérivé de pyrazoloquinoline pour traiter la maladie à corps de lewy - Google Patents

Agent thérapeutique contenant un dérivé de pyrazoloquinoline pour traiter la maladie à corps de lewy Download PDF

Info

Publication number
WO2018221551A1
WO2018221551A1 PCT/JP2018/020650 JP2018020650W WO2018221551A1 WO 2018221551 A1 WO2018221551 A1 WO 2018221551A1 JP 2018020650 W JP2018020650 W JP 2018020650W WO 2018221551 A1 WO2018221551 A1 WO 2018221551A1
Authority
WO
WIPO (PCT)
Prior art keywords
lewy body
dementia
disease
test
parkinson
Prior art date
Application number
PCT/JP2018/020650
Other languages
English (en)
Japanese (ja)
Inventor
舞 宮本
石川　幸雄
Original Assignee
エーザイ・アール・アンド・ディー・マネジメント株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーザイ・アール・アンド・ディー・マネジメント株式会社 filed Critical エーザイ・アール・アンド・ディー・マネジメント株式会社
Priority to CA3061884A priority Critical patent/CA3061884A1/fr
Priority to JP2019521251A priority patent/JP7269875B2/ja
Priority to ES18810202T priority patent/ES2961554T3/es
Priority to MX2019013397A priority patent/MX2019013397A/es
Priority to RU2019135690A priority patent/RU2802212C2/ru
Priority to EP18810202.4A priority patent/EP3632438B1/fr
Priority to KR1020197033124A priority patent/KR20200010220A/ko
Priority to CN201880030146.7A priority patent/CN110612102A/zh
Priority to US16/611,374 priority patent/US11311530B2/en
Priority to BR112019023552-3A priority patent/BR112019023552A2/pt
Priority to AU2018278422A priority patent/AU2018278422B2/en
Priority to IL270357A priority patent/IL270357B2/en
Publication of WO2018221551A1 publication Critical patent/WO2018221551A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to a therapeutic agent for Lewy body dementia and Parkinson's disease associated with dementia, comprising a pyrazoloquinoline derivative having phosphodiesterase 9 (PDE9) inhibitory activity or a pharmaceutically acceptable salt thereof as an active ingredient. is there.
  • PDE9 phosphodiesterase 9
  • Lewy body dementia (DLB; Dementia with Lewy bodies), Parkinson's disease (PD), an abnormal inclusion body (Lewy body) mainly composed of ⁇ -synuclein appears in nerve cells. It is a progressive neurodegenerative disease that causes degeneration and shedding. When Lewy bodies are distributed in large amounts in the cerebral cortex, cognitive dysfunction develops, and when they are distributed in large numbers in the brain stem, Parkinsonism develops. Other symptoms include hallucinations, hallucinations, delusions, mental symptoms such as depressive symptoms, sleep disorders, and autonomic symptoms.
  • DLB Dementia with Lewy bodies
  • PD Parkinson's disease
  • Lewy body an abnormal inclusion body mainly composed of ⁇ -synuclein appears in nerve cells. It is a progressive neurodegenerative disease that causes degeneration and shedding.
  • Lewy bodies When Lewy bodies are distributed in large amounts in the cerebral cortex, cognitive dysfunction develops, and when they are distributed in large numbers in the brain stem, Parkinsonism develops
  • Lewy body dementia is diagnosed when dementia develops before or within 1 year of onset of Parkinsonism, but Parkinson's disease with dementia occurs when Parkinsonism has existed more than 1 year before the onset of dementia Diagnosed as (PDD; Parkinson disease with dementia).
  • PDD Parkinson disease with dementia
  • the diagnosis is different from Lewy body dementia, Parkinson's disease with dementia, and Parkinson's disease. These are considered to be the same disease and are collectively referred to as Lewy body disease (LBD).
  • LBD Lewy body disease
  • brain SPECT and FDG PET in addition to the posterior cingulate gyrus and parietotemporal cortex associated with Alzheimer's disease, decreased blood flow and abnormal glucose metabolism are seen in the occipital lobe including the visual region.
  • DAT dopamine transporter
  • Non-Patent Documents 5, 6, 7, and 8 there is no fundamental treatment that modifies the progress of brain lesions in Lewy body dementia and Parkinson's disease.
  • Parkinson's symptoms dopamine adjuvant therapy such as L-DOPA or surgery is performed.
  • the only approved indications for cognitive impairment are donepezil for dementia with Lewy bodies and rivastigmine for Parkinson's disease with dementia, including changes in cognitive function, psychiatric symptoms (hall hallucinations, delusions, apathy, depression) (Symptoms, behavioral symptoms) are also effective (see Non-Patent Documents 5, 6, 7, and 8).
  • Non-Patent Document 9 acetylcholinesterase inhibitors worsen Parkinson's symptoms
  • Pimavanserin a 5-HT 2A inverse agonist
  • atypical antipsychotics such as olanzapine, quetiapine, and risperidone
  • black box warnings that the risk of death increases when used to treat psychiatric symptoms of dementia in the elderly.
  • scopolamine is a muscarinic receptor inhibitor that blocks transmission in the acetylcholine nervous system.
  • the acetylcholine nervous system is involved in memory, attention, etc., healthy people and animals receiving scopolamine show dementia-like amnesia, and are attenuated by drugs used to treat cognitive impairment in Lewy body disease (See Non-Patent Documents 11 and 12).
  • 6-OHDA is a neurotoxin that selectively denatures dopaminergic and noradrenergic nerves.
  • a compound represented by formula (I) (hereinafter referred to as compound (I)) or a pharmaceutically acceptable salt thereof exhibits a PDE9 inhibitory action and is expected to be effective against Alzheimer's dementia (patent) Reference 1).
  • a PDE9 inhibitor showed a cognitive function improving effect in a novel object recognition test using scopolamine-induced cognitive impairment rats (see Non-Patent Document 14), a pyrazoloquinoline derivative that showed a cognitive function improving effect was unknown.
  • An object of the present invention is to provide a compound or a pharmaceutically acceptable salt thereof that exhibits an anti-dementia effect in an animal model and has the potential to be used as a therapeutic agent for Lewy body disease.
  • the present inventors have found that a pyrazoloquinoline derivative represented by the formula (I) or a pharmacologically thereof. It has been found that acceptable salts have the effect of suppressing cognitive dysfunction induced by scopolamine. In addition, the present inventors have found that the effect of improving cognitive function against Lewy body disease can be confirmed by evaluating using a 6-OHDA model.
  • the present invention relates to ⁇ 1> to ⁇ 4> below.
  • a therapeutic agent for Parkinson's disease associated with Lewy body dementia or dementia comprising a pharmaceutically acceptable salt thereof.
  • the pyrazoloquinoline derivative of the present invention or a pharmaceutically acceptable salt thereof exhibits an effect of suppressing cognitive dysfunction induced by scopolamine in a rat model of scopolamine-induced cognitive impairment, which is an animal model of Lewy body disease.
  • the pyrazoloquinoline derivative of the present invention or a pharmaceutically acceptable salt thereof is expected to show an effect of suppressing cognitive dysfunction in a 6-OHDA model that is an animal model of Lewy body disease. Therefore, the compound according to the present invention or a pharmaceutically acceptable salt thereof has applicability as a therapeutic agent for Lewy body disease.
  • the “pharmaceutically acceptable salt” in the present specification is not particularly limited as long as it forms a salt with the compound according to the present invention, and specifically, for example, an inorganic acid salt or an organic acid salt. Or acid addition salts, such as acidic amino acid salt, are mentioned.
  • the “pharmaceutically acceptable salt” means that an acid for one molecule of the compound is formed in the formed salt as long as the salt is formed in an appropriate ratio.
  • the number of molecules is not particularly limited, but in one embodiment, the acid is about 0.1 to about 5 molecules per molecule of the compound, and in another embodiment, the acid is about 0.001 molecule per molecule of the compound. In another embodiment, the acid is about 0.5, about 1, or about 2 molecules per molecule of the compound.
  • the inorganic acid salt include hydrochloride, hydrobromide, sulfate, nitrate, phosphate and the like.
  • Specific examples of the organic acid salt include, for example, acetate. Succinate, fumarate, maleate, tartrate, citrate, lactate, stearate, benzoate, methanesulfonate, p-toluenesulfonate, benzenesulfonate, etc. It is done.
  • acidic amino acid salts include aspartate and glutamate.
  • the pharmaceutical composition according to the present invention can be produced by mixing a pharmaceutically acceptable additive with compound (I) or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition according to the present invention can be produced in accordance with a known method such as the method described in the General Formulation of the 16th revised Japanese Pharmacopoeia.
  • the pharmaceutical composition according to the present invention can be appropriately administered to a patient according to its dosage form.
  • the dose of Compound (I) or a pharmaceutically acceptable salt thereof varies depending on the degree of symptoms, age, sex, body weight, dosage form / salt type, specific type of disease, etc. In the case of an adult, about 30 ⁇ g to 10 g orally per day, 100 ⁇ g to 5 g in one embodiment, 100 ⁇ g to 1 g in another embodiment, about 30 ⁇ g to 1 g by injection administration, 100 ⁇ g to 500 mg in one embodiment, In another embodiment, 100 ⁇ g to 300 mg is administered once or divided into several times.
  • Compound (I) can be produced, for example, by the method described in Patent Document 1.
  • Scopolamine (Wako Pure Chemical Industries) was administered at a dose of 0.7 mg / kg subcutaneously in saline as a medium 30 minutes before T1.
  • T1 the rats were habituated to an empty test apparatus for 3 minutes and then placed in the waiting room.
  • T2 a retention trial
  • T1 familiar object
  • new object the object not used in T1
  • T1 and T2 rat behavior was photographed with a digital video camera, and the total search time for each object was manually measured using a stopwatch. The behavior in which the rat approached the nose within 2 cm of the object and the nose was directed toward the object was defined as the search behavior.
  • the new object search rate of T2 is regarded as an amnestic index that reflects discrimination between a known object and a new object.
  • the difference between the disease state control group and the drug-only treatment group was analyzed using Dunnett's multiple comparison test (significant difference: #). p ⁇ 0.05 was judged as a statistically significant difference. Statistical analysis was performed using GraphPad Prism version 5.04 or 6.02.
  • the rats in the pathological condition control group showed a significant decrease in the new object search rate compared with the rats in the normal control group. This means that scopolamine induced memory impairment in rats.
  • Compound (I) showed a significant improvement effect of the new object search rate at 3.3 mg / kg and 10 mg / kg.
  • 6-OHDA model Male SD rats are used to create the 6-OHDA model. The rat is fixed to a stereotaxic apparatus under anesthesia, and after exposing the skull, a cannula is inserted into the brain. 6-OHDA dissolved in ascorbic acid-added physiological saline is infused over several minutes using a microinjection pump. In order to protect the noradrenaline nerve, desipramine is administered before 6-OHDA injection. 6-OHDA untreated rats are created by cannulating the same site in the brain. A few days after surgery, a new object recognition test or object position recognition test is performed. A new object recognition test is described in Ennacer etc.
  • the test method described in 47-51 is partially modified.
  • the object position recognition test was conducted in accordance with Dix Behavior Brain Research 99 (1999) pp.
  • the test method described in 191-200 is partially modified.
  • the object position recognition test is a cognitive function evaluation test system based on the voluntary behavioral characteristics of rodents that the search behavior increases when the environment where the object is placed changes even if it is a familiar object . In all tests, habituation to the experimental procedure is performed before the test date. In the running-in operation, the vehicle is administered with a medium, and an empty test apparatus (40 cm ⁇ 30 cm ⁇ 45 cm in height) is freely searched for a fixed time (several minutes to several tens of minutes).
  • T1 On the day of the test, Compound (I) is orally administered prior to the acquisition trial (T1).
  • T1 two identical objects installed in the test apparatus are freely searched for a predetermined time (several minutes). Rats are returned to their home cages and then a holding trial (T2) is performed.
  • T2 of the new object recognition test an object used in T1 (“familiar” object) and an object not used in T1 (“new” object) are installed one by one in the test apparatus, and these objects are set for a certain period of time (several minutes). ) Search freely.
  • T2 of the object position recognition test one of the two identical objects presented in T1 is changed to a new position and installed in the test apparatus.
  • the object is wiped with wet tissue containing ethanol after each experiment so that no clues of odor remain.
  • the behavior of rats at T1 and T2 is photographed with a digital video camera, and the total search time for each object is manually measured using a stopwatch.
  • the behavior in which the rat brings the nose close to within 2 cm of the object and the nose is directed toward the object is defined as a search behavior.
  • the new object search ratio of T2 is regarded as an amnestic index that reflects discrimination between a known object and a new object.
  • the new position search ratio of T2 is regarded as an amnestic index that reflects discrimination between a known position and a new position.
  • the new object search ratio and the new position object search ratio are calculated by the following formulas.
  • New object search ratio (%) No / (No + Fo) ⁇ 100
  • Fo Known object search time
  • New position object search ratio (%) Nl / (Nl + Fl) ⁇ 100
  • Fl Known position object search time
  • the new object search ratio or the new position object search ratio is compared between groups to confirm the effect of the compound (I).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un agent thérapeutique pour le traitement de la maladie à corps de Lewy, cet agent contenant de la (S)-7-(2-méthoxy-3,5-diméthylpyridin-4-yl)-1-(tétrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one, qui est représentée par la formule (I), ou un sel pharmaceutiquement acceptable de celle-ci.
PCT/JP2018/020650 2017-06-01 2018-05-30 Agent thérapeutique contenant un dérivé de pyrazoloquinoline pour traiter la maladie à corps de lewy WO2018221551A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA3061884A CA3061884A1 (fr) 2017-06-01 2018-05-30 Agent therapeutique contenant un derive de pyrazoloquinoline pour traiter la maladie a corps de lewy
JP2019521251A JP7269875B2 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体を含有するレビー小体病治療剤
ES18810202T ES2961554T3 (es) 2017-06-01 2018-05-30 Agente terapéutico para enfermedad con cuerpos de Lewy que contiene derivado de pirazoloquinolina
MX2019013397A MX2019013397A (es) 2017-06-01 2018-05-30 Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina.
RU2019135690A RU2802212C2 (ru) 2017-06-01 2018-05-30 Терапевтическое средство для лечения болезни телец леви, содержащее производное пиразолохинолина
EP18810202.4A EP3632438B1 (fr) 2017-06-01 2018-05-30 Agent thérapeutique contenant un dérivé de pyrazoloquinoline pour traiter la maladie à corps de lewy
KR1020197033124A KR20200010220A (ko) 2017-06-01 2018-05-30 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
CN201880030146.7A CN110612102A (zh) 2017-06-01 2018-05-30 含有吡唑并喹啉衍生物的路易氏体病治疗剂
US16/611,374 US11311530B2 (en) 2017-06-01 2018-05-30 Lewy body disease therapeutic agent containing pyrazoloquinoline derivative
BR112019023552-3A BR112019023552A2 (pt) 2017-06-01 2018-05-30 Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina
AU2018278422A AU2018278422B2 (en) 2017-06-01 2018-05-30 Lewy body disease therapeutic agent containing pyrazoloquinoline derivative
IL270357A IL270357B2 (en) 2017-06-01 2018-05-30 A therapeutic agent in Lewy body disease containing pyrazoloquinoline compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513727P 2017-06-01 2017-06-01
US62/513,727 2017-06-01

Publications (1)

Publication Number Publication Date
WO2018221551A1 true WO2018221551A1 (fr) 2018-12-06

Family

ID=64456542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/020650 WO2018221551A1 (fr) 2017-06-01 2018-05-30 Agent thérapeutique contenant un dérivé de pyrazoloquinoline pour traiter la maladie à corps de lewy

Country Status (13)

Country Link
US (1) US11311530B2 (fr)
EP (1) EP3632438B1 (fr)
JP (1) JP7269875B2 (fr)
KR (1) KR20200010220A (fr)
CN (1) CN110612102A (fr)
AU (1) AU2018278422B2 (fr)
BR (1) BR112019023552A2 (fr)
CA (1) CA3061884A1 (fr)
ES (1) ES2961554T3 (fr)
IL (1) IL270357B2 (fr)
MX (1) MX2019013397A (fr)
TW (1) TWI784006B (fr)
WO (1) WO2018221551A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11939328B2 (en) 2021-10-14 2024-03-26 Incyte Corporation Quinoline compounds as inhibitors of KRAS

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632437B1 (fr) 2017-06-01 2024-03-13 Eisai R&D Management Co., Ltd. Agent thérapeutique pour traiter la démence associant un dérivé de pyrazoloquinoline et de la mémantine
US11484502B2 (en) 2017-06-01 2022-11-01 Eisai R&D Management Co., Ltd. Pharmaceutical composition comprising PDE9 inhibitor
SG11201909595VA (en) 2017-06-01 2019-11-28 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013051639A1 (fr) * 2011-10-07 2013-04-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 Dérivé de pyrazoloquinoline
WO2014163147A1 (fr) * 2013-04-05 2014-10-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 Sel de dérivé de pyrazoloquinoline et son cristal

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5318759A (en) 1976-08-02 1978-02-21 Nisshin Oil Mills Ltd Method of making fried beancurd
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
ES2149989T3 (es) 1994-05-24 2000-11-16 Hoffmann La Roche Derivados triciclicos de dicarbonilo.
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
CA2494785A1 (fr) 2002-08-07 2004-02-19 Mitsubishi Pharma Corporation Composes de dihydropyrazolopyridine
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE102004004142A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
US20060035920A1 (en) 2004-05-28 2006-02-16 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
CN101268073B (zh) 2005-09-15 2011-10-19 Aska制药株式会社 杂环化合物、制备方法及其用途
ES2536906T3 (es) 2006-12-13 2015-05-29 Aska Pharmaceutical Co., Ltd. Derivado de quinoxalina
CN101557826A (zh) 2006-12-13 2009-10-14 Aska制药株式会社 泌尿系统疾病的治疗药
ATE540954T1 (de) 2007-05-11 2012-01-15 Pfizer Aminoheterocyclische verbindungen
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
EP2334684B1 (fr) 2008-09-08 2017-08-02 Boehringer Ingelheim International GmbH Pyrazolopyrimidines et leur utilisation pour le traitement de troubles du snc
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
KR20110132559A (ko) 2009-03-05 2011-12-08 아스텔라스세이야쿠 가부시키가이샤 퀴녹살린 화합물
JP5542196B2 (ja) 2009-03-31 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １−複素環−１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｐｄｅ９ａモジュレーターとしてのそれらの使用
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
CN103052639B (zh) 2010-08-12 2016-02-17 贝林格尔.英格海姆国际有限公司 6-环烷基-1,5-二氢-吡唑并[3,4-d]嘧啶-4-酮衍生物及其作为PDE9A抑制剂的用途
CN103097383B (zh) 2010-09-07 2015-09-16 安斯泰来制药株式会社 吡唑并喹啉化合物
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
PT2573073E (pt) 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
BR112015024075B1 (pt) 2013-04-05 2022-05-03 Eisai R&D Management Co., Ltd Compostos de piridinilpirazoloquinolina
US11484502B2 (en) 2017-06-01 2022-11-01 Eisai R&D Management Co., Ltd. Pharmaceutical composition comprising PDE9 inhibitor
EP3632437B1 (fr) 2017-06-01 2024-03-13 Eisai R&D Management Co., Ltd. Agent thérapeutique pour traiter la démence associant un dérivé de pyrazoloquinoline et de la mémantine
SG11201909595VA (en) 2017-06-01 2019-11-28 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013051639A1 (fr) * 2011-10-07 2013-04-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 Dérivé de pyrazoloquinoline
US8563565B2 (en) 2011-10-07 2013-10-22 Eisai R&D Management Co., Ltd. Pyrazoloquinoline derivatives
WO2014163147A1 (fr) * 2013-04-05 2014-10-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 Sel de dérivé de pyrazoloquinoline et son cristal

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
"(non-official translation) "materials in reporter meeting"", 9 March 2017 (2017-03-09), Japan (internet), XP055636315, Retrieved from the Internet <URL:https://www.eisai.co.jp/ir/library/presentations/pdf/4523_170309.pdf> [retrieved on 20191028] *
"(non-official translation) Chapter 7: Dementia with Lewy bodies (included Parkinson's disease)", DEMENTIA DISEASE TREATMENT GUIDELINES 2010, JAPANESE SOCIETY OF NEUROLOGY, 2010, pages 300 - 302, XP055636341, Retrieved from the Internet <URL:http://www.neurology-jp.org/guidlinem/degl/sinkei_degl_2010_08.pdf> *
"Dix Behavioural Brain Research", vol. 99, 1999, pages: 191 - 200
"General Rules for Preparations of the Japanese Pharmacopoeia", vol. 31, 1988, pages: 47 - 51
BERGMAN ET AL., CLIN. NEUROPHARMACOL., vol. 25, 2002, pages 107 - 110
BOURKE ET AL., ANN. PHARMACOTHER., vol. 32, 1998, pages 610 - 611
CUMMINGS ET AL., LANCET, vol. 383, 2014, pages 533 - 540
DUBOIS ET AL., MOVEMENT DISORDERS, vol. 27, 2012, pages 1230 - 1238
HUTSON ET AL., NEUROPHARMACOLOGY, vol. 61, 2011, pages 665 - 676
KADOWAKI ET AL., PSYCHOPHARMACOLOGY, vol. 230, 2013, pages 345 - 352
MCKEITH ET AL., LANCET, vol. 356, 2000, pages 2031 - 2036
MCKEITH ET AL., NEUROLOGY, vol. 65, 2005, pages 1863 - 1872
MORI ET AL., ANN. NEUROL, VOL., vol. 72, 2012, pages 41 - 52
PERRY, NEUROREPORT, vol. 5, 1994, pages 747 - 749
SAMBETH ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 572, 2007, pages 151 - 159
SHIMADA ET AL., NEUROLOGY, vol. 73, 2009, pages 273 - 278
SNYDER ET AL., ALZHEIMER'S & DEMENTIA, vol. 1, 2005, pages 126 - 135
TIRABOSCHI ET AL., NEUROLOGY, vol. 54, 2000, pages 407 - 411

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11939328B2 (en) 2021-10-14 2024-03-26 Incyte Corporation Quinoline compounds as inhibitors of KRAS

Also Published As

Publication number Publication date
MX2019013397A (es) 2020-02-07
US20200155541A1 (en) 2020-05-21
KR20200010220A (ko) 2020-01-30
CA3061884A1 (fr) 2019-10-29
RU2019135690A3 (fr) 2021-08-25
EP3632438A4 (fr) 2020-12-23
TWI784006B (zh) 2022-11-21
JP7269875B2 (ja) 2023-05-09
AU2018278422A1 (en) 2019-11-21
EP3632438A1 (fr) 2020-04-08
TW201902479A (zh) 2019-01-16
EP3632438B1 (fr) 2023-08-23
RU2019135690A (ru) 2021-07-13
US11311530B2 (en) 2022-04-26
IL270357A (fr) 2020-02-27
IL270357B1 (en) 2023-10-01
AU2018278422B2 (en) 2022-03-17
ES2961554T3 (es) 2024-03-12
JPWO2018221551A1 (ja) 2020-04-02
BR112019023552A2 (pt) 2020-06-02
IL270357B2 (en) 2024-02-01
CN110612102A (zh) 2019-12-24

Similar Documents

Publication Publication Date Title
Nguyen et al. Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
JP7269875B2 (ja) ピラゾロキノリン誘導体を含有するレビー小体病治療剤
KR102627787B1 (ko) 피라졸로퀴놀린 유도체와 도네페질을 병용한 치매 치료제
KR20160067103A (ko) 신경 장애를 치료하기 위한 토라세미드 및 바클로펜을 포함하는 조성물
Anand et al. The animal models of dementia and Alzheimer’s disease for pre-clinical testing and clinical translation
EP3632437B1 (fr) Agent thérapeutique pour traiter la démence associant un dérivé de pyrazoloquinoline et de la mémantine
Chen et al. GABAA receptors in the central nucleus of the amygdala are involved in pain-and itch-related responses
JP2020514313A (ja) 脆弱ｘ症候群の治療のためのプリドピジンの使用
RU2746871C2 (ru) Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств
Balducci et al. Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT 1A receptor antagonist WAY 100635
JP2022511365A (ja) 神経変性疾患の治療における神経保護剤としてのアセチルコリンエステラーゼ阻害剤及び５‐ｈｔ４受容体アゴニストの組合せ
WO2015060746A1 (fr) Combinaison pour traiter et/ou prévenir l&#39;apparition de troubles psychiques, cognitifs, comportementaux et neurologiques lors de maladies organiques du système nerveux central de genèse diverse
Nirogi et al. Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling
RU2802212C2 (ru) Терапевтическое средство для лечения болезни телец леви, содержащее производное пиразолохинолина
RU2784428C2 (ru) Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и мемантина
Chen et al. Original Reports
Growdon Acetylcholine in AD: Expectations meet reality

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18810202

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3061884

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019521251

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197033124

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019023552

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018278422

Country of ref document: AU

Date of ref document: 20180530

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2018810202

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018810202

Country of ref document: EP

Effective date: 20200102

WWE Wipo information: entry into national phase

Ref document number: 2019135690

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 112019023552

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20191108